Core Insights - Winvest Group Limited's subsidiary IQI Media Inc. has partnered with BioCalth International Inc. to enhance BioCalth's direct-to-consumer sales [1][2] - The partnership includes a content management agreement with profit-sharing incentives aimed at increasing revenue and brand recognition for BioCalth [2][3] - BioCalth has over 25 years of experience in the supplement industry, manufacturing patented products in the USA and exporting globally [3][4] Company Overview - BioCalth is launching its first ecommerce store to introduce its flagship product, calcium L-threonate, which has a 95% absorption rate verified by laboratory research at UCLA [4][5] - The ecommerce site for BioCalth can be accessed at https://biocalth.us/ [6] - Winvest Group Limited is focused on media, entertainment, and technology, with plans to upgrade to Nasdaq and pursue an IPO [7] Strategic Initiatives - IQI Media will implement a top-of-funnel (TOFU) strategy for social marketing to build awareness and trust for BioCalth's products [4][5] - BioCalth is expanding its manufacturing capabilities at its California plant, which is FDA-registered and GMP-certified, to provide services to other companies [4][5] - The integration of sales, data analytics, and backend management is part of BioCalth's core strategy for future growth [5]

Core Insights - USANA announced innovative new products, significant ingredient reformulations, and refreshed packaging at its 2025 Global Convention [1][3] - The introduction of the Health Professional Advisory Council aims to enhance product credibility and customer experience [5][6] Product Developments - New products include Circulate+, Core Aminos, Marine Collagen Peptides, and various Celavive skincare items [8] - Reformulated products consist of BiOmega, CellSentials, HealthPak, and several Celavive products [8] - Rebranded products include Celavive Creamy Foam Cleanser, Conditioning Makeup Remover, and Protective Day Cream/Lotion SPF 30 [8] Strategic Initiatives - The Health Professional Advisory Council will consist of industry experts to support product development and enhance customer experiences [5][6] - The company emphasizes its commitment to providing high-quality nutritional and lifestyle products, backed by over 30 years of trust [7]

Market Overview - The market faced challenges as technology and semiconductor stocks experienced significant selling, raising concerns about high valuations and the sustainability of the AI-driven rally [1] - The S&P 500 and Nasdaq Composite indices declined by 0.24% and 0.67%, respectively, indicating a cautious market sentiment [1] - There is a shift in focus towards value stocks due to the current market conditions [1] Value Stocks Evaluation - The Price to Cash Flow (P/CF) ratio is highlighted as an effective metric for evaluating value stocks, with companies like StoneCo Ltd. (STNE), CVS Health Corporation (CVS), Integer Holdings Corporation (ITGR), and USANA Health Sciences, Inc. (USNA) showing low P/CF ratios [2][10] - A low P/CF ratio indicates a favorable market price relative to the cash flow generated per share, making it a reliable indicator of financial health [5][10] Financial Health Indicators - Positive cash flow is essential for a company's liquidity, enabling it to manage debts, reinvest, and return value to shareholders, while negative cash flow indicates declining liquidity [7] - Analysts emphasize that cash flow is a more reliable measure than earnings, which can be influenced by accounting estimates and management practices [6] Value Investing Strategy - A comprehensive approach to value investing should include multiple metrics such as price-to-book ratio, price-to-earnings ratio, and price-to-sales ratio, alongside the P/CF ratio [8] - Stocks should be selected based on parameters like P/CF less than or equal to the industry median, a minimum price of $5, and a Zacks Rank of 1 or 2 for better performance potential [9][11][13] Company Performance Highlights - StoneCo has a Zacks Rank of 1, with a trailing four-quarter earnings surprise of 11.5%, and is projected to see sales and EPS growth of 7.6% and 10.4%, respectively [13][14] - CVS Health holds a Zacks Rank of 2, with a trailing earnings surprise of 22.6%, and is expected to grow sales and EPS by 4.7% and 16.6%, respectively [15] - Integer Holdings, also with a Zacks Rank of 2, anticipates sales and EPS growth of 7.8% and 20.4%, despite a 13.2% decline in share price over the past year [16] - USANA Health Sciences has a Zacks Rank of 2, with a trailing earnings surprise of 21.6%, and is projected to grow sales and EPS by 11.7% and 1.2%, respectively, despite a 21.1% decline in share price [17]

Core Insights - BioAdaptives, Inc. announced that its nootropic formula MyndMed™ has been certified clean by TruShield Laboratory Services, ensuring compliance with World Anti-Doping Agency (WADA) regulations [1][3][4] Company Overview - BioAdaptives, Inc. specializes in developing and marketing science-based natural health and wellness products for both humans and animals, focusing on innovative formulations that align with the body's natural processes [6] Product Certification - MyndMed™ underwent rigorous testing by TruShield™, a recognized provider of sports supplement testing, confirming that it contains no banned substances and meets high safety standards for competitive athletes [2][3] - The certification allows UFC athletes to use MyndMed™ confidently, knowing it complies with anti-doping regulations [4] Product Composition - MyndMed™ is formulated with a blend of botanical extracts, amino acids, and neuro-support nutrients aimed at supporting neurotransmitter balance, mitochondrial energy production, and neural resilience, particularly under the stress of professional competition [5]

Core Insights - BioAdaptives, Inc. announced that its nootropic formula MyndMed™ has been certified clean by TruShield™ Laboratory Services, ensuring compliance with World Anti-Doping Agency (WADA) standards [1][3] Group 1: Product Certification - MyndMed™ has undergone rigorous testing by TruShield™, confirming the absence of banned substances and meeting high safety standards for competitive athletes [2][3] - The certification allows UFC athletes to use MyndMed™ confidently, knowing it complies with anti-doping regulations [3][4] Group 2: Product Composition - MyndMed™ is formulated with a blend of botanical extracts, amino acids, and neuro-support nutrients aimed at supporting neurotransmitter balance and mitochondrial energy production [5] Group 3: Company Overview - BioAdaptives, Inc. focuses on developing science-based natural health products for humans and animals, leveraging research in stem cell biology and regenerative nutrition [6]

Core Insights - Abbott Laboratories' Nutrition business is experiencing strong growth and market share gains, driven by high demand for adult nutritional products that combine high protein and low sugar [1][7] - The global nutritional supplements market is projected to reach $704.28 billion by 2030, growing at a CAGR of 6.42% from 2025 to 2030, influenced by increased health consciousness post-COVID-19 and rising non-communicable diseases [2] - Abbott's brands, Ensure and Glucerna, are leading in the market for complete nutrition, while the Similac brand remains the top choice for pediatric nutrition in the U.S. [3][7] Company Performance - Abbott's adult Nutrition segment achieved 6.6% organic growth in Q2 2025, contributing to mid-single-digit organic growth overall [3][7] - Year-to-date, Abbott shares have increased by 16.5%, outperforming the industry growth of 5.9% and the S&P 500's 9.6% [6] Competitive Landscape - Nestlé's Nutrition business offers a wide range of products for all life stages, including infant formulas and adult nutritional drinks [4] - Danone specializes in Early Life Nutrition and Medical Nutrition, providing a variety of infant and child nutrition products as well as condition-specific solutions [5] Valuation Metrics - Abbott currently trades at a forward Price-to-Sales (P/S) ratio of 4.89X, below the industry average of 5.56X [8]

Core Insights - FitLife Brands, Inc. reported a 5% decrease in total revenue for Q2 2025, amounting to $16.1 million compared to $16.9 million in Q2 2024 [3][19] - The decline in online revenue was 7%, totaling $10.4 million, which represented 65% of total revenue for the quarter [3][19] - Gross margin decreased to 42.8% from 44.8% year-over-year, primarily due to increased merger and acquisition-related expenses [4][5][19] Financial Performance - Net income for Q2 2025 was $1.7 million, down from $2.6 million in Q2 2024, with basic and diluted earnings per share at $0.19 and $0.18, respectively [5][19] - Adjusted EBITDA decreased by 13% to $3.3 million compared to the same period in 2024, with trailing twelve months adjusted EBITDA at $13.4 million [6][19] - The company ended the quarter with $10.9 million in term loans and $6.6 million in cash, resulting in total net debt of $4.3 million, approximately 0.3x adjusted EBITDA [7][19] Brand Performance - Legacy FitLife revenue increased by 7% year-over-year, driven by a 17% increase in online revenue and a 1% increase in wholesale revenue [11][12] - MRC revenue decreased by 16% compared to Q2 2024, with significant declines in the Dr. Tobias brand and skin care brands due to reduced traffic and tariffs [13][14][15] - MusclePharm revenue decreased by 4%, with wholesale revenue down 6% and online revenue down 3%, although the company is investing in advertising to drive growth [17][18][24] Acquisition Activity - The company completed the acquisition of Irwin Naturals for $42.5 million on August 8, 2025, funded primarily through a new term loan and available cash [20][26] - Irwin Naturals generated approximately $60 million in revenue with a gross margin of about 35% for the trailing twelve months as of June 30, 2025 [25][26] - Management expects to achieve cost savings and improved gross margins as they integrate Irwin Naturals into their operations [26][27]

Vancouver, British Columbia – August 13, 2025 – TheNewswire - Pangea Natural Foods Inc. (CSE: PNGA) (OTC: PNGAF) ("Pangea" or the "Company") is pleased to announce that its subsidiary Amino Innovations successfully showcased its portfolio of science-backed, non-injectable peptide products at TheFitExpo in Anaheim, California. The event, held on August 2nd-3rd at the Anaheim Convention Center, attracted more than 20,000 attendees, including fitness enthusiasts, trainers, wellness professionals, and influence ...

Core Viewpoint - FitLife Brands, Inc. has successfully acquired substantially all assets of Irwin Naturals for a total consideration of $42.5 million, as approved by the US Bankruptcy Court [1][2]. Group 1: Acquisition Details - The acquisition was executed under Section 363 of the US Bankruptcy Code, allowing FitLife to acquire assets while assuming minimal liabilities [2]. - The funding for the acquisition included $35.75 million from a new term loan and revolving line of credit from First Citizens Bank, with the remainder sourced from FitLife's cash balances [2]. Group 2: Company Insights - FitLife Brands is a developer and marketer of nutritional supplements and wellness products, offering over 250 products primarily online and through various retail locations [3]. - The company is headquartered in Omaha, Nebraska, and targets health-conscious consumers [3]. Group 3: Management Commentary - Dayton Judd, Chairman and CEO of FitLife, expressed excitement about the acquisition, highlighting Irwin's strong brands and distribution capabilities, and anticipates it will drive revenue and earnings growth for the company [3].

Financial Data and Key Metrics Changes - Net sales for Q2 2025 were $1.3 billion, down 1.7% compared to 2024, but flat on a constant currency basis [7][24] - Adjusted EBITDA was $174 million, exceeding guidance, with an adjusted EBITDA margin of 13.8%, down 30 basis points year over year due to unfavorable currency impacts [24][27] - The company paid down $55 million in debt during the quarter, maintaining a total leverage ratio of slightly under three times as of June 30 [27][28] Business Line Data and Key Metrics Changes - Product innovation included the launch of Multi Burn, a non-pharmaceutical weight loss supplement, and the introduction of a healthy lifespan product [6][19] - Distributor growth initiatives led to strong engagement, with nearly 38,000 attendees at training events globally [9][10] - New distributor growth was flat year over year, but four out of five regions saw increases, with Latin America leading at 16% growth [9] Market Data and Key Metrics Changes - In North America, net sales were down 4%, primarily due to a 6% decline in year-over-year volumes, but July marked the first month of year-over-year volume growth since April 2021 [33][8] - Latin America reported a strong performance with constant currency net sales up 9%, despite reported net sales being down 1% [31] - EMEA net sales were flat on a reported basis, while Asia Pacific saw a 2% decline in reported net sales [32] Company Strategy and Development Direction - The company aims to transform into a data-driven wellness platform, integrating technology and personalized solutions to meet evolving consumer needs [4][5] - The acquisition of Link Biosciences is expected to enhance personalized supplement formulations, providing a competitive advantage [21] - The company is focused on expanding its product offerings and enhancing distributor engagement through digital tools and AI [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's transformation and noted signs of accelerating momentum in sales [5][8] - The outlook for Q3 includes projected net sales growth of 0.5% to 4.5% year over year, with adjusted EBITDA expected to be between $150 million and $160 million [38][39] - The company has raised and narrowed its full-year net sales guidance range to down 1% to up 3% year over year [39][40] Other Important Information - The company is integrating the Protocol app, which aims to enhance distributor-customer connections and provide personalized health insights [11][12] - The launch of the Protocol app is expected to create new monetization opportunities and attract a new customer segment [48][63] - The company plans to expand the Protocol platform globally, with regulatory assessments underway for key markets [68] Q&A Session Summary Question: What are the monetization strategies for the Protocol app? - Management indicated that the app will serve as a tool for distributors to enhance customer engagement and will have options for both product and app subscriptions [48][63] Question: How does the company view pricing in relation to competitors? - The company plans to take pricing in line with market conditions and has not seen significant pressure from competitors [56][58] Question: What are the plans for high-cost debt management? - The company is considering refinancing options for high-cost debt as market conditions improve [69]